Unlock stock picks and a broker-level newsfeed that powers Wall Street.
XETRA - Delayed Quote EUR

Carl Zeiss Meditec AG (AFX.DE)

Compare
58.75
-1.85
(-3.05%)
At close: April 1 at 5:35:06 PM GMT+2
Loading Chart for AFX.DE
  • Previous Close 60.60
  • Open 61.30
  • Bid 59.60 x 18700
  • Ask --
  • Day's Range 58.55 - 61.55
  • 52 Week Range 44.28 - 114.80
  • Volume 193,516
  • Avg. Volume 261,557
  • Market Cap (intraday) 5.143B
  • Beta (5Y Monthly) 1.12
  • PE Ratio (TTM) 29.23
  • EPS (TTM) 2.01
  • Earnings Date May 14, 2025
  • Forward Dividend & Yield 0.60 (0.99%)
  • Ex-Dividend Date Mar 27, 2025
  • 1y Target Est 60.59

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders. This segment also provides devices for general ophthalmological examination and care, including slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras; and devices for functional diagnostics, as well as digital products for storage, evaluation, and sharing of clinical data. In addition, this segment offers surgical ophthalmology products comprising surgical microscopes, biometers, phacoemulsification, and vitrectomy devices; intraocular lenses for cataract patients; and systems and consumables for laser eye surgery. The Microsurgery segment provides products and solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, neuro, dental, and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.

www.zeiss.com/meditec-ag/de/investor-relations.html?vaURL=www.zeiss.de/meditec-ag/ir

2,066

Full Time Employees

September 30

Fiscal Year Ends

Recent News: AFX.DE

View More

Performance Overview: AFX.DE

Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD Return

AFX.DE
30.25%
DAX P (^GDAXI)
13.21%

1-Year Return

AFX.DE
48.80%
DAX P (^GDAXI)
21.89%

3-Year Return

AFX.DE
59.48%
DAX P (^GDAXI)
56.02%

5-Year Return

AFX.DE
28.72%
DAX P (^GDAXI)
136.15%

Compare To: AFX.DE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AFX.DE

View More

Valuation Measures

Annual
As of 3/31/2025
  • Market Cap

    5.30B

  • Enterprise Value

    5.44B

  • Trailing P/E

    30.15

  • Forward P/E

    31.25

  • PEG Ratio (5yr expected)

    1.49

  • Price/Sales (ttm)

    2.61

  • Price/Book (mrq)

    2.60

  • Enterprise Value/Revenue

    2.63

  • Enterprise Value/EBITDA

    13.49

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.54%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    7.48%

  • Revenue (ttm)

    2.08B

  • Net Income Avi to Common (ttm)

    157.03M

  • Diluted EPS (ttm)

    2.01

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    20.29M

  • Total Debt/Equity (mrq)

    26.93%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: AFX.DE

View More

Company Insights: AFX.DE

Research Reports: AFX.DE

View More

People Also Watch